Onward Medical NV (CHIX:ONWDB) Gross Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ONWDB Onward Medical NV CHIX:ONWDB
20 GF Score
Price €6.12
GF Value €266.82
! 4 Warning Signs
View Full Analysis

What is Onward Medical NV Gross Loan?

Gross Loan only applies to banks.

CHIX:ONWDB
20GF Score
Onward Medical NV CHIX:ONWDB
Gross Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Onward Medical NV (CHIX:ONWDB) Overvalued in 2026?

Based on GuruFocus' analysis, Onward Medical NV stock appears to be undervalued. The current stock price of €6.12 is trading 97.7% below its estimated GF Value™ of €266.82.

Key valuation signals for CHIX:ONWDB:

  • Gross Loan:
  • GF Value™: €266.82 vs. price of €6.12 (97.7% below fair value)
  • GF Score™: 20/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONWDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Onward Medical NV Business Description

Address Schimmelt 2, Eindhoven, NH, NLD, NL-5656
Onward Medical NV is a Dutch medical technology company developing and commercializing therapies that aim to restore movement, function, and independence in people with spinal cord injury. Its core platform, ARC Therapy, uses targeted, programmed electrical stimulation of the spinal cord, delivered through implanted and non-invasive systems, to re-enable communication between the brain and the body. The company is developing both implantable neurostimulation devices and external, wearable stimulation technologies, and is pursuing regulatory clearances in the United States and Europe. Its target customers are spinal cord injury patients, along with the rehabilitation hospitals, clinicians, and research centers that treat them. Onward Medical generates revenue primarily through the sale of its therapeutic systems and related accessories, supplemented by research collaborations and grant funding, with commercialization efforts concentrated in Europe and the United States.
20GF Score

Get the complete analysis for CHIX:ONWDB

Gross Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.12
Price
€266.82
GF Value